Clinical Trial

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting blood intravenously, the antibody part of this product binds to the surface of EGFR and c-Met on tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enzymatically transported to the lysosome. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death. TQB6411 for injection is intended for the treatment of advanced malignant tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-20; most recent amendment 2026-01-18.
Status change: Not Yet Recruiting → Recruiting 2025-07-15
Trial Details
NCT Number NCT07043751
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Advanced Malignant Tumors
Enrollment 216 participants
Start Date 2025-07-15
Primary Completion 2027-12 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-21